SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Korean healthtech company MINISH Technology hosted a successful dental seminar and business briefing in Los Angeles on May 10th, marking its second international event and a key step in its North American expansion - following its successful launch in Tokyo.
Following its inaugural overseas seminar in Tokyo earlier this year, MINISH Veneers brought its advanced veneer solution and minimally invasive restorative philosophy to a U.S. audience. The six-hour event, held at The West Hollywood EDITION, welcomed more than 80 local dentists from across the U.S..
The program introduced MINISH veneers' proprietary restorative system, presented real-world clinical cases, and outlined the company's plans to build a provider network in the U.S. Speakers also shared insights into practice models from established MINISH veneers providers in Asia and the company's broader North American strategy.
"To present our solution in one of the world's most advanced dental markets is an incredible milestone," said a MINISH spokesperson. "With our first U.S. provider clinic already operating in Los Angeles, we're now focused on expanding our footprint across North America."
MINISH Veneers currently operates 75 provider clinics worldwide, including 43 in Korea, 29 in Japan, and one clinic each in the U.S., Canada, and Vietnam. Out of the respondents, more than 81% of dentists present at the seminar expressed interest in joining the MINISH veneers provider network.
About MINISH Technology
MINISH Technology Co., Ltd. is a Seoul-based healthtech company offering cutting-edge solutions in restorative and aesthetic dentistry. Its signature MINISH system restores damaged teeth with precision-fabricated restorations that preserve natural tooth structure.
In addition to its clinical platform, MINISH operates the MINISH Veneers Course for dentist education, manages the MINISH Provider network, and invests in R&D across dental materials, equipment, and digital oral health technologies.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MINISH Veneers Expands Global Footprint with Successful Dental Seminar in Los Angeles
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
